X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson’s Disease Therapy
Gainesville, United States, June 23rd, 2026, FinanceWire X-tosis Receives Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Novel Parkinson’s Disease Therapy. The ward supports advancement of X-tosis’s mitochondrial approach and accelerates development of its lead Parkinson’s candidate toward the clinic. X-tosis, Inc., a precision-medicine biotechnology company founded in 2024 and dedicated to developing novel mitochondrial therapeutics for neurodegenerative diseases, today announced it has been awarded a $2.74 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through its Parkinson’s Disease Therapeutics Pipeline Program. The…
Read More